Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc.ELDN · Entity 6160 | General Counsel, Corporate Sec | January 10, 2025 | January 13, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eledon Pharmaceuticals, Inc.
Report date January 10, 2025 · Filed January 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.04 · Expires 2035-01-10 | Direct | 150,500 |
Reported balance
After 2025-01-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-01-10 · Grant · Acquired 150,500 · Balance 150,500 F1: This option represents a right to purchase up to 150,000 shares of common stock, which option vests with respect to 37,625 shares on January 10, 2026, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending January 10, 2029, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 64,500 |
Reported balance
After 2025-01-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-01-10 · Grant · Acquired 64,500 · Balance 64,500 F2: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration. F3: Represents shares issuable on settlement of restricted stock units ("RSUs"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase up to 150,000 shares of common stock, which option vests with respect to 37,625 shares on January 10, 2026, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending January 10, 2029, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.
F2: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration.
F3: Represents shares issuable on settlement of restricted stock units ("RSUs"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Urovant Sciences Ltd.
Report date March 29, 2021 · Filed March 31, 2021
Section 16 reporting ended · disclosed 2021-03-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-03-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-03-29 · Disposition to issuer · Disposed 9,341 · Balance 0 F1: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. |
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-03-29 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2021-03-29 · Disposition to issuer · Disposed 115,106 · Balance 0 F2: Immediately prior to the consummation of the Merger, these securities were time-based restricted share units ("RSUs") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan. Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in Common Shares prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. F1: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.53 · Expires 2028-05-20 | Direct | 0 |
Reported balance
After 2021-03-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-03-29 · Disposition to issuer · Disposed 93,450 · Balance 0 F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.65 · Expires 2028-10-14 | Direct | 0 |
Reported balance
After 2021-03-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-03-29 · Disposition to issuer · Disposed 3,500 · Balance 0 F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.88 · Expires 2029-01-06 | Direct | 0 |
Reported balance
After 2021-03-29 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-03-29 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
F2: Immediately prior to the consummation of the Merger, these securities were time-based restricted share units ("RSUs") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan. Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in Common Shares prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 10, 2025 Filed Jan 13, 2025 17:30 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantRestricted Stock Units · Derivative | 64,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-004921 · ownership.xml · derivative · entry 2 Smith Bryan E. · CIK 0001748041 · General Counsel, Corporate Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,500 Underlying: Common Stock · 64,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration. F3 · derivative.exercise_date: Represents shares issuable on settlement of restricted stock units ("RSUs"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. F3 · derivative.expiration_date: Represents shares issuable on settlement of restricted stock units ("RSUs"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 17:30 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 150,500 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0000950170-25-004921 · ownership.xml · derivative · entry 1 Smith Bryan E. · CIK 0001748041 · General Counsel, Corporate Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,500 Underlying: Common Stock · 150,500 shares Expires 2035-01-10 F1 · derivative.exercise_date: This option represents a right to purchase up to 150,000 shares of common stock, which option vests with respect to 37,625 shares on January 10, 2026, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending January 10, 2029, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| November 21, 2024 Filed Nov 22, 2024 17:00 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 474,350 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0000950170-24-130278 · ownership.xml · derivative · entry 1 Smith Bryan E. · CIK 0001748041 · General Counsel, Corporate Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 474,350 Underlying: Common Stock · 474,350 shares Expires 2033-05-01 F1 · derivative.exercise_date: This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 474,350 shares of underlying Common Stock on November 21, 2024 and time-based vesting criteria with respect to 177,881 shares of underlying Common Stock on November 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 296,469 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 17:00 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 241,650 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0000950170-24-073767 · ownership.xml · derivative · entry 1 Smith Bryan E. · CIK 0001748041 · General Counsel, Corporate Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,650 Underlying: Common Stock · 241,650 shares Expires 2033-05-01 F1 · derivative.exercise_date: This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 241,650 shares of underlying Common Stock on June 13, 2024 and time-based vesting criteria with respect to 60,413 shares of underlying Common Stock on May 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 181,237 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027. Read SEC document |
| May 01, 2023 Filed May 2, 2023 18:50 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 179,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001209191-23-026734 · doc4.xml · derivative · entry 1 Smith Bryan E. · CIK 0001748041 · General Counsel, Corporate Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,000 Underlying: Common Stock · 179,000 shares Expires 2033-05-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 179,000 shares of Common Stock, which option vests with respect to 44,750 shares on May 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending May 1, 2027. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 17:43 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 155,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001209191-23-006309 · doc4.xml · derivative · entry 1 Smith Bryan E. · CIK 0001748041 · General Counsel, Corporate Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2033-02-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 155,000 shares of Common Stock, which option vests with respect to 38,750 shares on February 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending February 1, 2027. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 17:37 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001209191-22-006489 · doc4.xml · derivative · entry 1 Smith Bryan E. · CIK 0001748041 · General Counsel, Corporate Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 120,000 shares of Common Stock, which option vests with respect to 30,000 shares on February 1, 2023, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending February 1, 2026. Read SEC document |
| May 03, 2021 Filed May 4, 2021 16:27 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 158,500 | $0.00 Strike: $9.91 | $0.00 |
DisclosureSEC source: 0000899243-21-018105 · doc4.xml · derivative · entry 1 Smith Bryan E. · CIK 0001748041 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,500 Underlying: Common Stock · 158,500 shares Expires 2031-05-03 F1 · derivative.exercise_date: This option represents a right to purchase up to 158,500 shares of Common Stock, which option vests with respect to 39,625 shares on May 3, 2022, and then with respect to 6.25% of the underlying shares quarterly over the three year period ending May 3, 2025. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 12:30 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0000899243-21-014103 · doc4.xml · derivative · entry 5 Smith Bryan E. · CIK 0001748041 · GC/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 20,000 shares Expires 2029-01-06 F3 · derivative.exercise_date: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 12:30 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $13.65 | $0.00 |
DisclosureSEC source: 0000899243-21-014103 · doc4.xml · derivative · entry 4 Smith Bryan E. · CIK 0001748041 · GC/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 3,500 shares Expires 2028-10-14 F3 · derivative.exercise_date: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 12:30 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | Disposition to issuerStock Option (Right to Buy) · Derivative | 93,450 | $0.00 Strike: $7.53 | $0.00 |
DisclosureSEC source: 0000899243-21-014103 · doc4.xml · derivative · entry 3 Smith Bryan E. · CIK 0001748041 · GC/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 93,450 shares Expires 2028-05-20 F3 · derivative.exercise_date: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 12:30 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | Disposition to issuerCommon Shares | 115,106 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014103 · doc4.xml · nonDerivative · entry 2 Smith Bryan E. · CIK 0001748041 · GC/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · security: Immediately prior to the consummation of the Merger, these securities were time-based restricted share units ("RSUs") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan. Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in Common Shares prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. F1 · price: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 12:30 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | Disposition to issuerCommon Shares | 9,341 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014103 · doc4.xml · nonDerivative · entry 1 Smith Bryan E. · CIK 0001748041 · GC/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 18:29 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | Tax withholdingCommon Shares | 4,761 | $16.09 | $76,604.49 |
DisclosureSEC source: 0001209191-21-002817 · doc4.xml · nonDerivative · entry 1 Smith Bryan E. · CIK 0001748041 · GC/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,447 F1 · shares: Represents shares of common stock withheld by the Issuer to pay tax withholding obligations of the Reporting Person upon the vesting of restricted stock units previously granted to the Reporting Person. Read SEC document |
| May 01, 2020 Filed May 4, 2020 16:55 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | GrantCommon Shares | 77,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-026841 · doc4.xml · nonDerivative · entry 1 Smith Bryan E. · CIK 0001748041 · GC/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,606 F1 · shares: 25% of the Restricted Stock Units shall vest on May 1, 2021; the remaining Restricted Stock Units vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 18:42 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0000899243-20-005516 · doc4.xml · derivative · entry 4 Smith Bryan E. · CIK 0001748041 · GC/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 50,000 shares Expires 2029-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 18:42 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | OtherCommon Shares | 15,165 | $13.08 | $198,358.20 |
DisclosureSEC source: 0000899243-20-005516 · doc4.xml · nonDerivative · entry 3 Smith Bryan E. · CIK 0001748041 · GC/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F2 · kind: Represents the sale of 15,165 shares of common stock to Sumitovant Biopharma Ltd., a subsidiary of Dainippon Sumitomo Pharma, in a privately-negotiated transaction. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 18:42 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | Tax withholdingCommon Shares | 34,835 | $13.08 | $455,641.80 |
DisclosureSEC source: 0000899243-20-005516 · doc4.xml · nonDerivative · entry 2 Smith Bryan E. · CIK 0001748041 · GC/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,165 F1 · kind: Represents 26,300 shares surrendered to the Issuer in satisfaction of payment of exercise price and 8,535 shares surrendered to the Issuer in satisfaction of the payment of required withholding taxes in connection with the exercise of stock options. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 18:42 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | Exercise / conversionCommon Shares | 50,000 | $6.88 | $344,000.00 |
DisclosureSEC source: 0000899243-20-005516 · doc4.xml · nonDerivative · entry 1 Smith Bryan E. · CIK 0001748041 · GC/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 16:30 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | GrantCommon Shares | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-000881 · doc4.xml · nonDerivative · entry 1 Smith Bryan E. · CIK 0001748041 · GC/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: 25% of the Restricted Stock Units shall vest on January 7, 2021; the remaining Restricted Stock Units vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. Read SEC document |
| January 06, 2019 Filed Jan 8, 2019 17:23 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0000899243-19-000778 · doc4.xml · derivative · entry 1 Smith Bryan E. · CIK 0001748041 · GC/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Shares · 70,000 shares Expires 2029-01-06 F1 · derivative.exercise_date: 25% of the total shares underlying the option shall vest and become exercisable on January 2, 2020; the remaining shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 18:10 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | GrantStock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $13.65 | $0.00 |
DisclosureSEC source: 0001209191-18-055414 · doc4.xml · derivative · entry 1 Smith Bryan E. · CIK 0001748041 · GC of Urovant Sciences,Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Shares · 3,500 shares Expires 2028-10-14 F1 · derivative.exercise_date: 25% of the total shares underlying the option shall vest and become exercisable on October 1, 2019; the remaining shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.